FDA Approves Daraxonrasib Drug for Pancreatic Cancer Treatment
· World · New York Times, Wall Street Journal, Reuters
The FDA has approved daraxonrasib, a new pill that significantly improves survival rates for pancreatic cancer patients. In a key clinical trial, patients who received the medication lived twice as long as those treated with standard chemotherapy. The breakthrough offers a new therapeutic option for one of the most difficult-to-treat malignancies.
Why it matters
Pancreatic cancer patients gain a viable new treatment option that extends life expectancy significantly compared to traditional chemotherapy.
Read the original report — New York Times
Join us on Telegram
Breaking news the moment it lands. At 10,000 members we ship the Android app.